{
    "Trade/Device Name(s)": [
        "Sejoy Blood Glucose Monitoring System",
        "Sejoy Advance Link Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Sejoy Biomedical Co., Ltd",
    "510(k) Number": "K240640",
    "Predicate Device Reference 510(k) Number(s)": [
        "K193475"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "September 6, 2024",
    "Summary Letter Received Date": "September 6, 2024",
    "Submission Date": "August 20, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Sejoy Blood Glucose Meter",
        "Sejoy Advance Link Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric detection",
        "Electrochemical reaction with glucose dehydrogenase"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip",
        "Control Solution",
        "Lancing Device",
        "Lancet"
    ],
    "Document Summary": "FDA 510(k) summary for Sejoy Blood Glucose Monitoring System and Sejoy Advance Link Blood Glucose Monitoring System for home self-testing of blood glucose using amperometric technology",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from the fingertip for self-testing by individuals with diabetes at home as an aid to monitor diabetes control; not for diagnosis, screening, or neonatal use",
    "fda_folder": "Clinical Chemistry"
}